Companies with investigational gene therapies under regulatory review in the EU may be forgiven if they feel less bullish about the commercial prospects for their products today than they did a few days ago. The news that bluebird bio is to wind down commercial initiatives for its gene therapy business in Europe after failing for two years to secure reimbursement for its approved gene therapy Zynteglo (betibeglogene autotemcel) for transfusion-dependent beta-thalassemia (TDT) will have set nerves on edge.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?